Skip to content

Blog

Alzheimer's Blood Test (p-tau217) With No Symptoms: Should You Get One? What a Result Really Means (2026)

You watched it happen to a parent. Maybe a grandparent too. First they repeated a story. Then they got lost on a drive they’d made a thousand times. Then, slowly, they became someone else. Now you’re 52, and you walked into a room and forgot why. Your mind goes straight to one place.

Then you find out you can order an Alzheimer’s blood test online. No doctor visit, a few hundred dollars, results in a couple of weeks. For many people that feels like a lifeline: finally, I can know.

That urge is very human, and this article won’t lecture you for it. But almost nothing written about these tests is written for the person who feels fine and is thinking about ordering one anyway. Company pages are selling a test. News stories cover FDA clearances for people with symptoms. Medical guidelines mostly say “not recommended” and stop there.

This guide covers the gap. It explains what the tests measure, how accurate they are in people without symptoms, what a positive or negative result really means in numbers, how APOE4 fits in, what knowing does to people psychologically, the insurance consequence most people discover too late, and how to decide. We don’t sell tests, and we have no relationship with any lab or company mentioned.

TL;DR

  • All four FDA-cleared Alzheimer’s blood tests are cleared only for people who already have cognitive symptoms. None is cleared for screening healthy people. Consumer companies still sell p-tau217 tests to people without symptoms, usually for $200–$800.
  • A positive result in someone who feels fine usually means amyloid is present. It doesn’t mean dementia is coming on any set timeline. In a 2026 JAMA analysis of 2,684 cognitively healthy adults, very high p-tau217 carried an estimated 38% five-year risk of cognitive impairment. Low levels carried about 10%.
  • A negative result isn’t a guarantee. It lowers the chance of Alzheimer’s-type changes now. It doesn’t rule out other causes of dementia or changes in the future.
  • No treatment is proven to prevent symptoms in people who test positive while healthy. The two major prevention trials (TRAILBLAZER-ALZ 3 and AHEAD 3-45) aren’t expected to finish their main analyses until late 2027 and late 2028.
  • The best things to do for your brain don’t depend on the result: blood pressure, LDL cholesterol, hearing, exercise, sleep, blood sugar, not smoking, and staying socially connected.
  • In the U.S., the insurance gap is real. GINA doesn’t protect you from life, disability, or long-term care insurers. If you’re going to test, think about those policies first.
  • The strongest reason to test without symptoms is to join a prevention trial. Those programs usually test you for free and include counseling.

The Short Answer: Should You Get an Alzheimer’s Blood Test If You Have No Symptoms?

For most people right now, no. Or at least, not until you can answer one question: “What would I do differently with each possible result?”

That isn’t because the tests are bad. p-tau217 is one of the most impressive blood biomarkers in all of neurology. The problem is that for people who feel fine, the science of reading the result is still moving fast, and the science of acting on it hasn’t caught up.

Here’s the decision in one table:

Your situation Is a p-tau217 blood test useful? What to do
You or your family have noticed real changes in memory or thinking Yes, as part of a medical workup See a clinician. The cleared tests are designed for exactly this.
You want to join an Alzheimer’s prevention trial Yes. This is the strongest reason to test while healthy. Search the Alzheimer’s Association TrialMatch or ClinicalTrials.gov. Trials often test and counsel you for free.
A parent had Alzheimer’s, you feel fine, and you’d use a result for concrete life planning Possibly, after thinking it through Read the insurance section first. Consider genetic counseling. Test through a clinician, not alone.
You’re anxious about memory and hoping for reassurance Often counterproductive A negative result can’t promise you a future, and a positive one can’t be undone. Talk to your doctor about the anxiety and the lapses.
You’re curious and it’s an add-on in a longevity panel Low value Skip it, or decide in advance what you’d do with each result before you add it.
You have chronic kidney disease Results are harder to interpret Only test through a clinician who knows your kidney function.

Wondering which preventive tests are actually worth your time and money? Answer a few quick, non-identifying questions and get personalized eligibility guidance across all 6 categories ScanGlean covers. Take the Fit Check →

What an Alzheimer’s Blood Test Actually Measures

Alzheimer’s disease has two hallmark protein problems in the brain. Amyloid plaques build up between nerve cells, and tau tangles form inside them. Amyloid usually comes first, often 15 to 20 years or more before memory symptoms.

When amyloid builds up, brain cells start releasing a specific form of the tau protein called phosphorylated tau 217 (p-tau217). Some of it leaks into the blood in tiny amounts. Modern lab methods can measure those amounts, and p-tau217 turns out to track amyloid in the brain very closely. That’s why it’s the headline marker in most current tests.

Other markers you may see on a report:

  • Amyloid-beta 42/40 ratio. A drop in this blood ratio suggests amyloid is being trapped in the brain. On its own it’s less accurate than p-tau217. Some tests combine the two, such as Fujirebio’s Lumipulse pTau217/Aβ42 ratio and C2N’s PrecivityAD2.
  • p-tau181. An older tau marker, a bit less accurate than p-tau217.
  • GFAP and NfL. Markers of brain inflammation and nerve damage. They aren’t specific to Alzheimer’s. NfL rises in many conditions.
  • APOE genotype. Not a biomarker at all. It’s a gene test, and it tells you about lifetime risk rather than current brain changes. More on it below.

One thing to understand from the start: these tests mainly detect amyloid. Amyloid isn’t the same as dementia. Amyloid is very common in older brains that work perfectly well. A 2015 JAMA meta-analysis (Jansen and colleagues) estimated that about 10% of cognitively normal 50-year-olds and 44% of cognitively normal 90-year-olds have amyloid pathology. Rates were 2 to 3 times higher in APOE4 carriers.

Which Alzheimer’s Blood Tests Are FDA-Cleared? (And for Whom)

As of October 2026, the FDA has cleared four blood tests to help evaluate Alzheimer’s disease:

Test Maker Cleared Measures Cleared for
Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio Fujirebio May 2025 p-tau217 ÷ Aβ42 ratio Adults 55+ with signs and symptoms of cognitive decline, in specialty care
Elecsys pTau181 Roche (with Eli Lilly) October 2025 p-tau181 Ruling out Alzheimer’s changes in primary care, for people with symptoms
PrecivityAD2 C2N Diagnostics August 2026 Amyloid and tau ratios (mass spectrometry) Symptomatic adults, as young as 40
Elecsys pTau217 Roche (with Eli Lilly) August 24, 2026 p-tau217 Adults 55+ with signs, symptoms, or complaints of cognitive decline, in primary and specialty care

Notice the common thread: every one of them is for people who already have symptoms. When the FDA announced the first clearance in May 2025, it said plainly that the test is “not intended as a screening or stand-alone diagnostic test.” The Alzheimer’s Association’s first clinical practice guideline on blood biomarkers (July 2025) was written for specialists evaluating people with cognitive impairment. It recommends tests with at least 90% sensitivity and 75% specificity for ruling Alzheimer’s changes out, and at least 90% for both before a blood test can replace a PET scan or spinal tap.

So how can you buy one when you have no symptoms? Most consumer offerings are laboratory-developed tests run under lab certification rules rather than FDA clearance, and a telehealth physician signs the order. That’s legal. It also means you’re stepping outside the use the tests were validated for.

How Accurate Is p-tau217 If You Feel Fine?

Accuracy depends a lot on who is being tested. This is the most important and least explained point in the whole topic.

In people with symptoms: very good

In the FDA’s review of Lumipulse, based on 499 samples from cognitively impaired adults, 91.7% of positive results were confirmed by amyloid PET or spinal fluid, and 97.3% of negative results were confirmed negative. Fewer than 20% of people got an “indeterminate” result in the gray zone. That’s the setting these tests were built for.

In people without symptoms: good, but noticeably weaker

The largest study of this question was published in JAMA Neurology in November 2025 (Salvadó and colleagues). It pooled 2,916 cognitively unimpaired adults from 12 research cohorts, about a third of whom had amyloid.

  • A positive p-tau217 result on its own was correct about amyloid 79% of the time. Put another way, about 1 in 5 positives in healthy people didn’t have amyloid on PET or spinal fluid.
  • Adding a confirmatory PET scan or spinal fluid test for positives raised that to 91%.
  • Mass-spectrometry tests did somewhat better overall than the more common immunoassays.

Why is it worse in healthy people? Partly because fewer of them have amyloid. When a condition is less common, any test produces a higher share of false positives. Partly because early, low-level amyloid sits right around the cutoffs. And the 79% figure came from research cohorts, which tend to include people with family histories. In the general population, where amyloid is rarer, the share of false positives would likely be higher still.

Things that can throw off your result

  • Kidney function. Your kidneys help clear p-tau from the blood. Studies from the Mayo Clinic Study of Aging (Mielke and colleagues, Nature Medicine, 2022) and Sweden’s BioFINDER cohort found chronic kidney disease raises p-tau217 and p-tau181 even in people without amyloid. Ratio-based tests are affected less.
  • Different labs, assays, and populations. Cutoffs aren’t interchangeable between tests, and they don’t always travel well. In a Mayo Clinic and Wisconsin study presented in December 2025 (Algeciras-Schimnich and colleagues), the FDA-cleared Lumipulse cutoffs reached 85% specificity in a research cohort. In a real-world clinic group, specificity fell to 23%, meaning most people without amyloid were flagged positive. Using lab-specific cutoffs fixed most of the problem.
  • Lab quality. In December 2025, Fujirebio began a Class II recall of certain Lumipulse plasma ratio lots after customers saw more positive and indeterminate results than expected, with falsely elevated ratios. The FDA posted it in February 2026. A single number from a single draw is not infallible.
  • Indeterminate results. Depending on the test, roughly 10% to 20% of people land in a gray zone. That’s an answer of “we can’t tell,” and for an anxious person it can be the worst outcome of all.

What a Positive or Negative Result Actually Means: The Real Numbers

This is the part no sales page shows you, so we’ll go slowly.

If your result is positive

The best data we have is a large pooled analysis published in JAMA in July 2026 (Buckley, Sperling, and colleagues). It followed 2,684 cognitively unimpaired adults from six long-running studies, average age about 70, for up to 13.5 years. Researchers grouped people by blood p-tau217 level and estimated how many would develop mild cognitive impairment or dementia.

  • People with very high p-tau217 had an estimated 38% risk of progressing within five years.
  • In the preprint version of the same analysis, estimated 10-year risks for an average participant were about 20% with low p-tau217, 22% intermediate, 39% high, and 61% very high. The published version cautions that estimates beyond five years rest on sparse data.

Read those numbers two ways. First, high p-tau217 is a genuine and strong risk signal, and the risk climbs with the level. Second, even at the highest levels, a large share of people did not develop impairment within five years. At low and intermediate levels, risk barely differed.

There’s also a timing clue. A February 2026 study in Nature Medicine (Petersen, Schindler, and colleagues; 603 older adults) built a “clock” model from p-tau217. It estimated when symptoms might begin, with a margin of error of about 3 to 4 years. Age mattered a lot. When p-tau217 turned positive at about age 60, symptoms followed on average about 20 years later. When it turned positive at 80, symptoms followed about 11 years later. (The test used was developed by a company two of the authors co-founded. The authors said the model needs refinement before individual clinical use.)

Earlier modeling work points the same way. A 2018 study by UCLA biostatisticians Brookmeyer and Abdalla in Alzheimer’s & Dementia concluded that most people with amyloid alone will not develop Alzheimer’s dementia in their lifetime. That’s mainly because the process is slow and other causes of death often come first, especially when amyloid appears later in life.

In plain terms: a positive p-tau217 result at 55 and at 80 mean very different things. At 55, it may be the earliest sign of a process that unfolds over two decades. At 80, it may be a finding you’d likely live with for the rest of your life without dementia.

If your result is negative

A negative result is genuinely reassuring about one thing: you probably don’t have significant amyloid right now. Negative predictive values are high.

But there are three limits:

  1. It’s a snapshot. Amyloid can start building later. A normal result at 50 doesn’t describe you at 70.
  2. It covers only Alzheimer’s-type changes. Vascular dementia, Lewy body dementia, frontotemporal dementia, and other causes don’t show up on p-tau217.
  3. It doesn’t remove baseline risk. In the 2026 JAMA analysis, even the low p-tau217 group had an estimated 10% five-year risk of cognitive impairment from any cause. That reflects their age, which averaged about 70.

What testing healthy people at scale looks like

The TRAILBLAZER-ALZ 3 prevention trial screened healthy adults aged 55 to 80 using plasma p-tau217 alone. Of 57,110 people tested, about 10% met the trial’s elevated p-tau217 threshold. The rate rose steadily with age: about 4.5% at 55–59, 7.5% at 65–69, 12% at 70–74, 17% at 75–79, and 22% at 80–84 (Yaari and colleagues, Alzheimer’s & Dementia, 2025). Those people knew in advance they were joining a research program with counseling and follow-up. People ordering a test online usually get neither.

Experts don’t agree on what to call a positive result

In 2024, an Alzheimer’s Association workgroup (Jack and colleagues) proposed defining Alzheimer’s biologically. Under that view, an abnormal core biomarker such as p-tau217 means Alzheimer’s disease, even without symptoms. Later that year, the International Working Group (Dubois and colleagues, JAMA Neurology) pushed back. It argued that cognitively normal people with positive biomarkers should be described as “at risk,” because most of them never develop symptoms.

That disagreement affects you directly. Depending on which framework your clinician or testing company follows, the same number could be described to you as a disease or as a risk factor.

APOE4: The Gene Test That Often Comes Bundled In

Many longevity panels and consumer DNA kits include APOE, a gene with three common versions: ε2, ε3, and ε4. You inherit one copy from each parent.

APOE genotype Approx. share of people of European ancestry Estimated risk of Alzheimer’s by age 85*
No ε4 ~75% Population average is about 11% for men and 14% for women. It’s lower for people without ε4.
One ε4 (e.g., ε3/ε4) ~20–25% ~23% (men) to ~30% (women)
Two ε4 (ε4/ε4) ~2–3% ~51% (men) to ~60% (women)

*From Genin and colleagues, Molecular Psychiatry, 2011, using U.S. incidence data. French data gave somewhat higher female estimates (35% and 68%). Frequencies vary by ancestry.

A 2024 study in Nature Medicine (Fortea and colleagues; about 3,300 people in the pathology analysis and more than 10,000 in the clinical analysis) argued that two copies of APOE4 should be considered a distinct genetic form of Alzheimer’s. Nearly all ε4/ε4 carriers showed Alzheimer’s biology by 65, and symptoms began at an average age of about 65. Even so, symptoms started anywhere across a span of roughly 49 to 81, and some ε4/ε4 carriers live into old age without dementia.

How APOE differs from p-tau217: APOE never changes. It’s a lifelong risk modifier, not a sign that anything is happening now. p-tau217 reflects what’s happening in your brain at the moment. Plenty of APOE4 carriers never get Alzheimer’s, and plenty of people with no ε4 copies do.

APOE4 also matters if you’re ever treated with an anti-amyloid drug. Carriers, and especially ε4/ε4 carriers, have higher rates of ARIA, a side effect involving brain swelling or small bleeds. Specialists test for APOE before prescribing these drugs for that reason.

The Psychology of Knowing: What Actually Happens to People

The research here is more reassuring, and more nuanced, than either side of the debate tends to admit.

Most people cope well, especially with counseling. In the REVEAL trial (Green and colleagues, New England Journal of Medicine, 2009), 162 adults with a parent who had Alzheimer’s were randomized to learn their APOE results or not. Over a year, the two groups showed no significant differences in anxiety, depression, or test-related distress. Carriers had a brief bump in distress at six weeks that faded by six months. Similar short-term findings came from disclosing amyloid PET results to healthy participants in the A4 prevention study.

But those studies had guardrails most consumers don’t get. REVEAL participants were screened beforehand. People with high baseline anxiety or depression were more likely to struggle, and the most distressed were often excluded. Every result came with in-person genetic counseling. The study’s editorialists still wrote that this particular test “warrants extra caution.”

Knowing can change how your memory seems to work. In a 2014 study in the American Journal of Psychiatry (Lineweaver and colleagues), healthy older adults who knew they carried APOE4 rated their memory as worse and scored worse on objective memory tests than carriers who didn’t know their status. Labels shape perception. After a positive result, every lost key and forgotten name can start to feel like evidence.

Reassurance-seeking rarely ends with one test. If you’re testing mainly to quiet a fear, consider how you’d react to an indeterminate result, a “borderline” one, or a negative one next to a sibling’s positive. Anxiety tends to find the next question. Many people get more relief from a proper conversation with a clinician about the specific lapses that worry them. Many common lapses turn out to come from sleep, stress, mood, medications, or hearing loss.

Being told “no” can feel paternalistic. Taking that seriously is fair. Some people genuinely want to know, and they plan well with the information. They decide when to retire, have conversations with family, write advance directives, travel sooner, or join research. Those are legitimate reasons. The point isn’t that you shouldn’t want to know. It’s that you should choose knowing on purpose, with support, rather than add it to a cart at 1 a.m.

Is There Anything You Can Do If You Test Positive?

This is the heart of the “should I test” question, so here’s an honest answer in three parts.

1. No drug is proven to prevent symptoms in healthy people who test positive

The two FDA-approved anti-amyloid antibodies, lecanemab (Leqembi) and donanemab (Kisunla), are approved only for mild cognitive impairment or mild dementia with confirmed amyloid. They modestly slowed decline in that population, and they carry real risks, including ARIA.

For people without symptoms, the evidence is still pending:

  • The A4 study gave solanezumab, an earlier anti-amyloid antibody, to more than 1,100 amyloid-positive healthy adults for about 4.5 years. It did not slow cognitive decline (Lilly announcement, March 2023; Sperling and colleagues, NEJM, 2023). Solanezumab removed little amyloid, so the result doesn’t settle the question for stronger drugs.
  • TRAILBLAZER-ALZ 3 (donanemab, 2,196 participants) has an estimated primary completion date of November 2027.
  • AHEAD 3-45 (lecanemab) has an estimated primary completion date of December 2028.

If those trials succeed, the calculation behind testing healthy people will change quickly. For now, a positive result can’t be “treated” outside a trial.

2. Risk-factor changes are worth doing, but they’re worth doing regardless of the result

The 2024 Lancet Commission on dementia (Livingston and colleagues) estimated that about 45% of dementia cases worldwide are linked to 14 modifiable risk factors. Those factors are less education, hearing loss, high LDL cholesterol, depression, traumatic brain injury, physical inactivity, diabetes, smoking, high blood pressure, obesity, excess alcohol, social isolation, air pollution, and untreated vision loss. The 45% figure assumes these links are causal, which isn’t fully proven, but the direction is consistent.

The best trial evidence comes from U.S. POINTER (Baker and colleagues, JAMA, 2025). It randomized 2,111 older adults at elevated risk to a structured or self-guided lifestyle program for two years. Both groups improved. The structured program, with regular aerobic exercise, strength training, a MIND-style diet, cognitive challenge, social engagement, and health monitoring, did better. The benefit held regardless of APOE4 status.

That’s the uncomfortable truth for people hoping a test will motivate them. The action plan for a positive result and a negative result is nearly the same. If a number is what finally gets you to treat your blood pressure, get hearing aids, and start lifting, that’s a real benefit. But you can start today without one.

3. A positive result can open the door to research

Prevention trials actively look for people with elevated biomarkers, and they usually provide testing, results disclosure, counseling, and monitoring for free. If you’re the kind of person who wants to know and wants to act, a trial is the most meaningful action available. See the Alzheimer’s Association’s TrialMatch service or ClinicalTrials.gov.

For the broader picture of which longevity tests change decisions and which don’t, see our evidence review of preventive health scans and longevity clinics and our guide to biological age tests.

The Insurance Trap Nobody Mentions (U.S.)

This is the most practical section in the article, and the one most often learned too late.

  • GINA (the Genetic Information Nondiscrimination Act, 2008) protects you from health insurers and most employers using genetic test results, including APOE.
  • GINA does not cover life insurance, disability insurance, or long-term care insurance. Federal law lets those insurers ask about genetic results and use them in underwriting. A handful of states have added limits. Florida, for example, restricted life and long-term care insurers’ use of genetic information in 2020. Protections vary widely, so check your state.
  • Biomarker tests like p-tau217 aren’t genetic tests, so GINA’s protections may not apply to them at all. A result in your medical record, or a cognitive concern noted in a chart, can come up on applications.
  • Insurers know people act on this information. In a 2005 study from the REVEAL group (Zick and colleagues, Health Affairs), people who learned they carried APOE4 were nearly six times as likely to buy long-term care insurance in the following year.

Practical steps if you’re considering testing:

  1. If you’d want long-term care or life insurance, think about applying before you test. Many genetic counselors advise exactly this.
  2. Ask whether the result will go into your medical record, and who the company can share data with. Consumer companies aren’t always bound by the same privacy rules as your doctor’s office.
  3. Read the company’s privacy policy for data sales, research use, and what happens to your data if the company is sold.

Outside the U.S., rules differ. The U.K., for instance, has a voluntary Code on Genetic Testing and Insurance with the insurance industry. Check local protections before you test.

How Much Does an Alzheimer’s Blood Test Cost in 2026?

Publicly advertised U.S. prices as of October 2026 (they change often):

Option What you get Advertised price
Labcorp-run p-tau217 via third-party ordering sites p-tau217 alone ~$240–$280
Lucent Diagnostics p-tau217 ~$300
Quest AD-Detect (consumer) Blood amyloid markers, telehealth order Launched at $399 in 2023
BetterBrain p-tau217 as a $200 add-on to a $399 plan (APOE +$100); 45+ only ~$600 total
Apollo Health Brainscan p-tau217, GFAP, NfL $799
C2N PrecivityAD2 Multi-marker mass spectrometry, FDA-cleared for symptomatic adults $1,450 list
Function Health p-tau217 and APOE as add-ons to a $365 membership Add-on pricing varies
Prevention trials Testing, disclosure, and counseling Usually free

Insurance: generally not covered when you have no symptoms. For people with cognitive symptoms, coverage is expanding now that FDA-cleared tests exist, but it still varies by plan. A blood test also costs far less than an amyloid PET scan, which often runs several thousand dollars.

How to Decide: Five Questions to Answer Before You Order

  1. What will I do if it’s positive? Name specific actions: join a trial, change retirement timing, talk to family, apply for long-term care insurance first. If the honest answer is “worry,” pause.
  2. What will I do if it’s negative? If you’d keep doing exactly what you do now, the test is buying peace of mind. Ask yourself whether it would really last.
  3. What will I do if it’s indeterminate? Roughly 1 in 10 to 1 in 5 people get one.
  4. Who will help me interpret it? Ideally a clinician who knows your history and kidney function. If APOE is involved, a genetic counselor.
  5. Have I handled insurance first? See the section above.

If you can answer all five clearly, testing is a reasonable, informed choice, and it’s yours to make. If you can’t, the most useful step today is probably a visit to your doctor about blood pressure, cholesterol, hearing, sleep, and mood.

And if you’re noticing real changes, such as getting lost, repeating questions, trouble managing bills, or changes that family members point out, that’s a different situation entirely. See a clinician soon. Many causes of memory problems are treatable, including vitamin B12 deficiency, thyroid disease, depression, sleep apnea, and medication side effects. If it is Alzheimer’s, the cleared blood tests and approved treatments are designed for exactly that stage, and earlier evaluation helps.

The Bottom Line

Alzheimer’s blood tests are a real scientific breakthrough. For people with symptoms, they’re quickly replacing expensive PET scans and spinal taps, and they help people get answers sooner.

For people who feel fine, a p-tau217 test answers a narrower question than it seems to: is amyloid probably present in my brain right now? It can’t tell you whether you’ll get dementia or when. No treatment yet is proven to change the outcome for healthy people who test positive. And the steps that protect your brain are nearly identical whatever the result says.

That doesn’t make wanting to know wrong. It makes it a choice that deserves the same care as any other big decision. That means counseling, a plan for every possible result, and, in the U.S., attention to insurance before testing rather than after.

If you’re building a broader prevention plan, our evidence-based longevity plan for your 40s covers the risk factors that matter for both heart and brain. Our guide to heart attack prevention scans covers LDL and blood pressure, which matter for dementia as well.

Frequently Asked Questions

Can a blood test detect Alzheimer’s before symptoms?

It can detect Alzheimer’s-related brain changes, especially amyloid plaques, often years before symptoms. It can’t tell you whether or when you’ll develop dementia. Plasma p-tau217 rises when amyloid builds up in the brain, and in people without symptoms it correctly identifies amyloid most of the time. In a 2025 JAMA Neurology study of 2,916 cognitively healthy adults, a positive p-tau217 result alone was right about amyloid 79% of the time. But many people with amyloid never develop dementia in their lifetime. All four FDA-cleared Alzheimer’s blood tests are cleared only for people who already have cognitive symptoms.

Should I get a p-tau217 test if I have no memory problems?

For most people, not yet. The Alzheimer’s Association’s 2025 clinical guideline covers only people with cognitive impairment, and the FDA labels on cleared tests say they are not for screening. The main reason is that no treatment has been proven to prevent or delay symptoms in people who test positive while they still feel well. The two big prevention trials of anti-amyloid drugs aren’t expected to report before late 2027 and 2028. The strongest reason to test without symptoms is to join one of those prevention trials. Research programs often test you for free and give you counseling.

How accurate is the p-tau217 blood test?

In people who already have symptoms, the best tests agree with amyloid PET scans or spinal fluid about 90% of the time or better. In the FDA review of the Lumipulse test, 91.7% of positive results and 97.3% of negative results were confirmed, though under 20% of people got an indeterminate result. In people without symptoms, accuracy is lower, partly because fewer of them have amyloid. Kidney disease can raise p-tau217 without any Alzheimer’s changes. Accuracy also varies a lot between labs and assays.

What does a positive Alzheimer’s blood test mean if I feel fine?

It usually means you probably have amyloid in your brain. It doesn’t mean you have dementia or will definitely get it. A large 2026 JAMA analysis of 2,684 cognitively healthy adults found that people with very high p-tau217 had about a 38% estimated risk of developing cognitive impairment within five years, versus roughly 10% for people with low levels. Risk rises with the level and with age. Many people with moderately elevated results stay cognitively normal for a decade or longer.

Should I get tested for the APOE4 gene?

Only if you’ve thought through what you’d do with the answer. Roughly 1 in 4 people carries one copy of APOE4, and about 2 to 3% carry two copies. In a well-known 2011 analysis, the estimated risk of Alzheimer’s by age 85 was about 23–30% for one copy and 51–60% for two copies, depending on sex, versus about 11–14% for the general population. In the U.S., APOE results can legally be used by life, disability, and long-term care insurers, so many genetic counselors suggest getting those policies in place before testing.

How much does an Alzheimer’s blood test cost, and does insurance cover it?

Consumer p-tau217 tests in the U.S. typically cost about $200 to $800. Prices advertised in 2025–2026 include about $240–$280 for Labcorp-run p-tau217 through ordering sites, $300 for Lucent, a $200 add-on to BetterBrain’s $399 plan, and $799 for Apollo Health’s Brainscan panel. C2N’s PrecivityAD2 lists at $1,450. Insurance generally doesn’t cover testing in people without symptoms. Coverage for people with symptoms is growing now that the FDA has cleared several tests.

If my test is positive, is there anything I can do?

Yes, though nothing has been proven to stop Alzheimer’s biology in people without symptoms. The 2024 Lancet Commission estimated that about 45% of dementia cases worldwide are linked to 14 modifiable risk factors, including high blood pressure, hearing loss, high LDL cholesterol, physical inactivity, smoking, diabetes, depression, and social isolation. In the U.S. POINTER trial (2,111 older adults, 2 years), a structured lifestyle program improved cognition, and the benefit held regardless of APOE4 status. A positive result can also qualify you for prevention trials.

Can an Alzheimer’s or APOE test result affect my insurance?

In the U.S., the Genetic Information Nondiscrimination Act (GINA) stops health insurers and most employers from using genetic test results such as APOE. It does not cover life, disability, or long-term care insurance, and a few states have added their own protections. Biomarker tests like p-tau217 aren’t genetic tests, so GINA may not protect them at all. A result in your medical record can come up when you apply for these policies. In one study, people who learned they carried APOE4 were nearly six times as likely to buy long-term care insurance afterward. Insurers know this, which is why underwriting questions matter.


This article is for general educational and informational purposes only. It is not medical, genetic, legal, or insurance advice and is not a substitute for diagnosis or guidance from a licensed physician, genetic counselor, or other qualified professional. Risk estimates come from research populations, often with more family history and less diversity than the general public, and may not apply to you. Insurance protections differ by country and U.S. state. Prices reflect publicly advertised U.S. rates as of October 2026 and change frequently. If you’re experiencing memory or thinking changes, please see a clinician. See our Methodology page for how we research and update articles like this one.

Disclosure

ScanGlean does not sell tests, panels, or memberships, and we have no paid, affiliate, or referral relationship with Fujirebio, Roche, Eli Lilly, C2N Diagnostics, Quest Diagnostics, Labcorp, Lucent Diagnostics, BetterBrain, Apollo Health, Function Health, or any other company mentioned in this article. If that changes, it will be disclosed here and on our Methodology page.

Sources

← Back to all guides

Newsletter

Before you go — get new comparisons first.

One email when we publish a new provider comparison, cost guide, or evidence review. No spam, no clinic promotions.